Clinical Trial Update: M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating M6620 in combination with carboplatin, with or without docetaxel, for metastatic castration-resistant prostate cancer; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• M6620 (berzosertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-08